Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Heterocyclic Compounds, 3-Ring"" wg kryterium: Temat


Tytuł :
Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis.
Autorzy :
Rubbert-Roth A; From the Division of Rheumatology, Cantonal Clinic St. Gallen, St. Gallen, Switzerland (A.R.-R.); AbbVie, North Chicago, IL (J.E., A.L.P., N.K., Y.Z., N.M.); Centre Hospitalier de l'Université de Montréal, Montreal (B.H.); Queen Elizabeth Hospital and University of Adelaide, Adelaide, SA, Australia (M.R.); and Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (R.M.X.).
Enejosa J; From the Division of Rheumatology, Cantonal Clinic St. Gallen, St. Gallen, Switzerland (A.R.-R.); AbbVie, North Chicago, IL (J.E., A.L.P., N.K., Y.Z., N.M.); Centre Hospitalier de l'Université de Montréal, Montreal (B.H.); Queen Elizabeth Hospital and University of Adelaide, Adelaide, SA, Australia (M.R.); and Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (R.M.X.).
Pangan AL; From the Division of Rheumatology, Cantonal Clinic St. Gallen, St. Gallen, Switzerland (A.R.-R.); AbbVie, North Chicago, IL (J.E., A.L.P., N.K., Y.Z., N.M.); Centre Hospitalier de l'Université de Montréal, Montreal (B.H.); Queen Elizabeth Hospital and University of Adelaide, Adelaide, SA, Australia (M.R.); and Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (R.M.X.).
Haraoui B; From the Division of Rheumatology, Cantonal Clinic St. Gallen, St. Gallen, Switzerland (A.R.-R.); AbbVie, North Chicago, IL (J.E., A.L.P., N.K., Y.Z., N.M.); Centre Hospitalier de l'Université de Montréal, Montreal (B.H.); Queen Elizabeth Hospital and University of Adelaide, Adelaide, SA, Australia (M.R.); and Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (R.M.X.).
Rischmueller M; From the Division of Rheumatology, Cantonal Clinic St. Gallen, St. Gallen, Switzerland (A.R.-R.); AbbVie, North Chicago, IL (J.E., A.L.P., N.K., Y.Z., N.M.); Centre Hospitalier de l'Université de Montréal, Montreal (B.H.); Queen Elizabeth Hospital and University of Adelaide, Adelaide, SA, Australia (M.R.); and Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (R.M.X.).
Khan N; From the Division of Rheumatology, Cantonal Clinic St. Gallen, St. Gallen, Switzerland (A.R.-R.); AbbVie, North Chicago, IL (J.E., A.L.P., N.K., Y.Z., N.M.); Centre Hospitalier de l'Université de Montréal, Montreal (B.H.); Queen Elizabeth Hospital and University of Adelaide, Adelaide, SA, Australia (M.R.); and Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (R.M.X.).
Zhang Y; From the Division of Rheumatology, Cantonal Clinic St. Gallen, St. Gallen, Switzerland (A.R.-R.); AbbVie, North Chicago, IL (J.E., A.L.P., N.K., Y.Z., N.M.); Centre Hospitalier de l'Université de Montréal, Montreal (B.H.); Queen Elizabeth Hospital and University of Adelaide, Adelaide, SA, Australia (M.R.); and Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (R.M.X.).
Martin N; From the Division of Rheumatology, Cantonal Clinic St. Gallen, St. Gallen, Switzerland (A.R.-R.); AbbVie, North Chicago, IL (J.E., A.L.P., N.K., Y.Z., N.M.); Centre Hospitalier de l'Université de Montréal, Montreal (B.H.); Queen Elizabeth Hospital and University of Adelaide, Adelaide, SA, Australia (M.R.); and Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (R.M.X.).
Xavier RM; From the Division of Rheumatology, Cantonal Clinic St. Gallen, St. Gallen, Switzerland (A.R.-R.); AbbVie, North Chicago, IL (J.E., A.L.P., N.K., Y.Z., N.M.); Centre Hospitalier de l'Université de Montréal, Montreal (B.H.); Queen Elizabeth Hospital and University of Adelaide, Adelaide, SA, Australia (M.R.); and Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (R.M.X.).
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2020 Oct 15; Vol. 383 (16), pp. 1511-1521.
Typ publikacji :
Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Abatacept/*therapeutic use
Antirheumatic Agents/*therapeutic use
Arthritis, Rheumatoid/*drug therapy
Heterocyclic Compounds, 3-Ring/*therapeutic use
Inducible T-Cell Co-Stimulator Protein/*antagonists & inhibitors
Janus Kinase Inhibitors/*therapeutic use
Abatacept/adverse effects ; Administration, Oral ; Antirheumatic Agents/adverse effects ; Arthritis, Rheumatoid/blood ; C-Reactive Protein/analysis ; Double-Blind Method ; Drug Tolerance ; Female ; Heterocyclic Compounds, 3-Ring/adverse effects ; Humans ; Infusions, Intravenous ; Intention to Treat Analysis ; Janus Kinase Inhibitors/adverse effects ; Male ; Middle Aged ; Remission Induction
Czasopismo naukowe
Tytuł :
Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV.
Autorzy :
Correa A; Medical Sciences College, University of Pernambuco, Recife, Pernambuco, Brazil.
Monteiro P; Medical Sciences College, University of Pernambuco, Recife, Pernambuco, Brazil.
Calixto F; Teaching Hospital Oswaldo Cruz, University of Pernambuco, Recife, Pernambuco, Brazil.
Batista JDL; Medical Sciences College, Federal University of Fronteira Sul, Chapecó, Santa Catarina, Brazil.
de Alencar Ximenes RA; Medical Sciences College, University of Pernambuco, Recife, Pernambuco, Brazil.; Post-Graduation Program in Tropical Medicine, Federal University of Pernambuco, Recife, Pernambuco, Brazil.
Montarroyos UR; Institute of Biological Sciences, University of Pernambuco, Recife, Pernambuco, Brazil.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Aug 31; Vol. 15 (8), pp. e0238052. Date of Electronic Publication: 2020 Aug 31 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Safety*
Anti-HIV Agents/*adverse effects
Anti-HIV Agents/*pharmacology
HIV Infections/*drug therapy
HIV Infections/*virology
Heterocyclic Compounds, 3-Ring/*adverse effects
Heterocyclic Compounds, 3-Ring/*pharmacology
Adolescent ; Adult ; Aged ; Anti-HIV Agents/therapeutic use ; Female ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Virology
Czasopismo naukowe
Tytuł :
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
Autorzy :
Bollen PDJ; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, Netherlands.
Moore CL; Medical Research Council Clinical Trials Unit, University College London, London, UK.
Mujuru HA; University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe.
Makumbi S; Joint Clinical Research Centre, Mbarara, Uganda.
Kekitiinwa AR; Baylor College of Medicine Children's Foundation, Kampala, Uganda.
Kaudha E; Joint Clinical Research Centre, Kampala, Uganda.
Parker A; Medical Research Council Clinical Trials Unit, University College London, London, UK.
Musoro G; University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe.
Nanduudu A; Joint Clinical Research Centre, Kampala, Uganda.
Lugemwa A; Joint Clinical Research Centre, Mbarara, Uganda.
Amuge P; Baylor College of Medicine Children's Foundation, Kampala, Uganda.
Hakim JG; University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe.
Rojo P; Hospital 12 de Octubre, Madrid, Spain.
Giaquinto C; University of Padova, Padova, Italy.
Colbers A; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, Netherlands. Electronic address: .
Gibb DM; Medical Research Council Clinical Trials Unit, University College London, London, UK.
Ford D; Medical Research Council Clinical Trials Unit, University College London, London, UK.
Turkova A; Medical Research Council Clinical Trials Unit, University College London, London, UK.
Burger DM; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, Netherlands.
Pokaż więcej
Corporate Authors :
ODYSSEY trial team
Źródło :
The lancet. HIV [Lancet HIV] 2020 Aug; Vol. 7 (8), pp. e533-e544.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
HIV Infections/*drug therapy
HIV Integrase Inhibitors/*administration & dosage
Heterocyclic Compounds, 3-Ring/*administration & dosage
Adolescent ; Body Weight ; Child ; Dose-Response Relationship, Drug ; Female ; HIV Integrase Inhibitors/adverse effects ; HIV Integrase Inhibitors/pharmacokinetics ; HIV Integrase Inhibitors/therapeutic use ; Heterocyclic Compounds, 3-Ring/adverse effects ; Heterocyclic Compounds, 3-Ring/pharmacokinetics ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Humans ; Male ; Tablets ; Uganda ; Zimbabwe
Czasopismo naukowe
Tytuł :
Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.
Autorzy :
Rodriguez-Gonzalez CG; Pharmacy Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria del Hospital Gregorio Marañón, Madrid, Spain.
Chamorro-de-Vega E; Pharmacy Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria del Hospital Gregorio Marañón, Madrid, Spain.
Ortega-Navarro C; Pharmacy Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria del Hospital Gregorio Marañón, Madrid, Spain.
Alonso R; Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria del Hospital Gregorio Marañón, Madrid, Spain.
Herranz-Alonso A; Pharmacy Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria del Hospital Gregorio Marañón, Madrid, Spain.
Sanjurjo-Saez M; Pharmacy Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria del Hospital Gregorio Marañón, Madrid, Spain.
Pokaż więcej
Źródło :
The Annals of pharmacotherapy [Ann Pharmacother] 2020 Jul; Vol. 54 (7), pp. 633-643. Date of Electronic Publication: 2020 Jan 08.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Anti-HIV Agents/*therapeutic use
Dideoxynucleosides/*therapeutic use
HIV Infections/*drug therapy
Heterocyclic Compounds, 3-Ring/*therapeutic use
Lamivudine/*therapeutic use
Adult ; Anti-HIV Agents/administration & dosage ; Anti-HIV Agents/adverse effects ; Anti-HIV Agents/economics ; Cohort Studies ; Cost-Benefit Analysis ; Dideoxynucleosides/administration & dosage ; Dideoxynucleosides/adverse effects ; Dideoxynucleosides/economics ; Drug Combinations ; Female ; HIV Infections/virology ; HIV-1/drug effects ; Heterocyclic Compounds, 3-Ring/administration & dosage ; Heterocyclic Compounds, 3-Ring/adverse effects ; Heterocyclic Compounds, 3-Ring/economics ; Humans ; Lamivudine/administration & dosage ; Lamivudine/adverse effects ; Lamivudine/economics ; Male ; Proportional Hazards Models ; Retrospective Studies ; Tablets ; Treatment Outcome
Czasopismo naukowe
Tytuł :
ABCG2 Deficiency Does Not Alter Dolutegravir Metabolism and Pharmacokinetics.
Autorzy :
Zhu J; Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy (J.Z., X.T., A.I.S., X.M.) and Division of Infectious Disease, Department of Medicine (D.K.M.), University of Pittsburgh, Pittsburgh, Pennsylvania.
Tian X; Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy (J.Z., X.T., A.I.S., X.M.) and Division of Infectious Disease, Department of Medicine (D.K.M.), University of Pittsburgh, Pittsburgh, Pennsylvania.
Shehu AI; Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy (J.Z., X.T., A.I.S., X.M.) and Division of Infectious Disease, Department of Medicine (D.K.M.), University of Pittsburgh, Pittsburgh, Pennsylvania.
McMahon DK; Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy (J.Z., X.T., A.I.S., X.M.) and Division of Infectious Disease, Department of Medicine (D.K.M.), University of Pittsburgh, Pittsburgh, Pennsylvania.
Ma X; Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy (J.Z., X.T., A.I.S., X.M.) and Division of Infectious Disease, Department of Medicine (D.K.M.), University of Pittsburgh, Pittsburgh, Pennsylvania .
Pokaż więcej
Źródło :
The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2020 Jul; Vol. 374 (1), pp. 38-43. Date of Electronic Publication: 2020 Apr 17.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
ATP Binding Cassette Transporter, Subfamily G, Member 2/*deficiency
ATP Binding Cassette Transporter, Subfamily G, Member 2/*genetics
Heterocyclic Compounds, 3-Ring/*metabolism
Animals ; Gene Deletion ; Heterocyclic Compounds, 3-Ring/pharmacokinetics ; Mice ; Organ Specificity ; Tissue Distribution
Czasopismo naukowe
Tytuł :
Dolutegravir-associated hyperglycaemia in patients with HIV.
Autorzy :
Lamorde M; Infectious Diseases Institute, Makerere University College of Health Sciences, PO Box 22418, Kampala, Uganda. Electronic address: .
Atwiine M; Infectious Diseases Institute, Makerere University College of Health Sciences, PO Box 22418, Kampala, Uganda.
Owarwo NC; Infectious Diseases Institute, Makerere University College of Health Sciences, PO Box 22418, Kampala, Uganda.
Ddungu A; Infectious Diseases Institute, Makerere University College of Health Sciences, PO Box 22418, Kampala, Uganda.
Laker EO; Infectious Diseases Institute, Makerere University College of Health Sciences, PO Box 22418, Kampala, Uganda.
Mubiru F; Infectious Diseases Institute, Makerere University College of Health Sciences, PO Box 22418, Kampala, Uganda.
Kiragga A; Infectious Diseases Institute, Makerere University College of Health Sciences, PO Box 22418, Kampala, Uganda.
Lwanga IB; Infectious Diseases Institute, Makerere University College of Health Sciences, PO Box 22418, Kampala, Uganda.
Castelnuovo B; Infectious Diseases Institute, Makerere University College of Health Sciences, PO Box 22418, Kampala, Uganda.
Pokaż więcej
Źródło :
The lancet. HIV [Lancet HIV] 2020 Jul; Vol. 7 (7), pp. e461-e462. Date of Electronic Publication: 2020 Feb 24.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
MeSH Terms :
Anti-HIV Agents/*adverse effects
HIV Infections/*drug therapy
HIV Integrase Inhibitors/*adverse effects
Heterocyclic Compounds, 3-Ring/*adverse effects
Hyperglycemia/*chemically induced
Anti-HIV Agents/therapeutic use ; Female ; HIV Integrase Inhibitors/therapeutic use ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Humans ; Male ; Middle Aged
Czasopismo naukowe
Tytuł :
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Autorzy :
Orkin C; Queen Mary University of London, London, UK; Barts Health NHS Trust, Royal London Hospital, Ambrose King Centre, London, UK.
DeJesus E; Orlando Immunology Center, Orlando, FL, USA.
Sax PE; Division of Infectious Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Arribas JR; Infectious Diseases Unit, Hospital Universitario La Paz, IdiPaz Madrid, Spain.
Gupta SK; Department of Medicine, Division of Infectious Diseases, Indiana University School of Medicine, Indianapolis, IN, USA.
Martorell C; The Research Institute, Springfield, MA, USA.
Stephens JL; Department of Internal Medicine, Mercer University School of Medicine, Macon, GA, USA.
Stellbrink HJ; Department of Internal Medicine, Infectious Diseases, University of Hamburg, Hamburg, Germany.
Wohl D; Department of Medicine, Institute of Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Maggiolo F; Unit of HIV-related Diseases and Experimental Therapies, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.
Thompson MA; AIDS Research Consortium of Atlanta, Atlanta, GA, USA.
Podzamczer D; Infectious Disease Department, Hospital Universitari de Bellvitge, Barcelona, Spain.
Hagins D; Georgia Department of Public Health, Coastal Health District, Chatham Care Center, Savannah, GA, USA.
Flamm JA; Department of Adult and Family Medicine, Kaiser Permanente Medical Group, Sacramento, CA, USA.
Brinson C; Central Texas Clinical Research, Austin, TX, USA.
Clarke A; Elton John Centre, Royal Sussex County Hospital, Brighton & Sussex University Hospitals NHS Trust, Brighton, UK.
Huang H; Department of Biometrics, Gilead Sciences, Foster City, CA, USA.
Acosta R; Department of Virology, Gilead Sciences, Foster City, CA, USA.
Brainard DM; Department of HIV Clinical Research, Gilead Sciences, Foster City, CA, USA.
Collins SE; Department of HIV Clinical Research, Gilead Sciences, Foster City, CA, USA. Electronic address: .
Martin H; Department of HIV Clinical Research, Gilead Sciences, Foster City, CA, USA.
Pokaż więcej
Corporate Authors :
GS-US-380-1489
GS-US-380-1490 study investigators
Źródło :
The lancet. HIV [Lancet HIV] 2020 Jun; Vol. 7 (6), pp. e389-e400.
Typ publikacji :
Clinical Trial, Phase III; Comparative Study; Equivalence Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenine/*analogs & derivatives
Dideoxynucleosides/*administration & dosage
Emtricitabine/*administration & dosage
HIV Infections/*drug therapy
Heterocyclic Compounds, 3-Ring/*administration & dosage
Heterocyclic Compounds, 4 or More Rings/*administration & dosage
Lamivudine/*administration & dosage
Tenofovir/*administration & dosage
Adenine/administration & dosage ; Adenine/adverse effects ; Adult ; Aged ; Dideoxynucleosides/adverse effects ; Double-Blind Method ; Drug Administration Schedule ; Drug Combinations ; Emtricitabine/adverse effects ; Female ; HIV Infections/virology ; HIV-1/genetics ; Heterocyclic Compounds, 3-Ring/adverse effects ; Heterocyclic Compounds, 4 or More Rings/adverse effects ; Humans ; Lamivudine/adverse effects ; Male ; Middle Aged ; RNA, Viral/blood ; Tenofovir/adverse effects ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial.
Autorzy :
Dooley KE; Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: .
Savic R; University of California San Francisco, San Francisco, CA, USA.
Gupte A; Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Marzinke MA; Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Zhang N; University of California San Francisco, San Francisco, CA, USA.
Edward VA; The Aurum Institute, Johannesburg, South Africa; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT, USA.
Wolf L; Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sebe M; The Aurum Institute, Johannesburg, South Africa.
Likoti M; The Aurum Institute, Johannesburg, South Africa.
Fyvie MJ; Vx Pharma, Pretoria, South Africa.
Shibambo I; Vx Pharma, Pretoria, South Africa.
Beattie T; The Aurum Institute, Johannesburg, South Africa.
Chaisson RE; Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Churchyard GJ; The Aurum Institute, Johannesburg, South Africa; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Pokaż więcej
Corporate Authors :
DOLPHIN Study Team
Źródło :
The lancet. HIV [Lancet HIV] 2020 Jun; Vol. 7 (6), pp. e401-e409. Date of Electronic Publication: 2020 Mar 30.
Typ publikacji :
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
HIV Infections/*drug therapy
Heterocyclic Compounds, 3-Ring/*administration & dosage
Isoniazid/*administration & dosage
Rifampin/*analogs & derivatives
Tuberculosis/*prevention & control
Adult ; Drug Administration Schedule ; Female ; HIV Infections/virology ; HIV-1/genetics ; Heterocyclic Compounds, 3-Ring/adverse effects ; Humans ; Isoniazid/adverse effects ; Male ; Middle Aged ; Rifampin/administration & dosage ; Rifampin/adverse effects ; South Africa ; Treatment Outcome ; Viral Load
Czasopismo naukowe
Tytuł :
Exposure-Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit-Risk Assessment in Rheumatoid Arthritis.
Autorzy :
Nader A; Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, Illinois, USA.
Mohamed MF; Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, Illinois, USA.
Winzenborg I; Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany.
Doelger E; Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany.
Noertersheuser P; Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany.
Pangan AL; Immunology Clinical Development, AbbVie, North Chicago, Illinois, USA.
Othman AA; Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, Illinois, USA.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2020 Apr; Vol. 107 (4), pp. 994-1003. Date of Electronic Publication: 2019 Nov 30.
Typ publikacji :
Clinical Trial, Phase II; Clinical Trial, Phase III; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antirheumatic Agents/*administration & dosage
Arthritis, Rheumatoid/*drug therapy
Heterocyclic Compounds, 3-Ring/*administration & dosage
Janus Kinase Inhibitors/*administration & dosage
Antirheumatic Agents/adverse effects ; Antirheumatic Agents/blood ; Arthritis, Rheumatoid/blood ; Arthritis, Rheumatoid/diagnosis ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Herpes Zoster/chemically induced ; Heterocyclic Compounds, 3-Ring/adverse effects ; Heterocyclic Compounds, 3-Ring/blood ; Humans ; Janus Kinase Inhibitors/adverse effects ; Janus Kinase Inhibitors/blood ; Male ; Pneumonia/chemically induced ; Risk Assessment/methods ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Exposure-Response Analyses for Upadacitinib Efficacy and Safety in the Crohn's Disease CELEST Study and Bridging to the Extended-Release Formulation.
Autorzy :
Mohamed MF; Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, Illinois, USA.
Klünder B; Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, Illinois, USA.
Lacerda AP; Immunology Development, AbbVie Inc., North Chicago, Illinois, USA.
Othman AA; Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, Illinois, USA.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2020 Mar; Vol. 107 (3), pp. 639-649. Date of Electronic Publication: 2019 Nov 22.
Typ publikacji :
Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Crohn Disease/*drug therapy
Heterocyclic Compounds, 3-Ring/*administration & dosage
Janus Kinase Inhibitors/*administration & dosage
Adult ; Crohn Disease/physiopathology ; Delayed-Action Preparations ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Heterocyclic Compounds, 3-Ring/adverse effects ; Heterocyclic Compounds, 3-Ring/pharmacokinetics ; Humans ; Janus Kinase Inhibitors/adverse effects ; Janus Kinase Inhibitors/pharmacokinetics ; Male ; Middle Aged ; Severity of Illness Index
Czasopismo naukowe
Tytuł :
High acceptability and viral suppression of patients on Dolutegravir-based first-line regimens in pilot sites in Uganda: A mixed-methods prospective cohort study.
Autorzy :
Nabitaka VM; Clinton Health Access Initiative, Kampala, Uganda.
Nawaggi P; Clinton Health Access Initiative, Kampala, Uganda.
Campbell J; Clinton Health Access Initiative, Kampala, Uganda.
Conroy J; Clinton Health Access Initiative, Kampala, Uganda.
Harwell J; Clinton Health Access Initiative, Kampala, Uganda.
Magambo K; Clinton Health Access Initiative, Kampala, Uganda.
Middlecote C; Clinton Health Access Initiative, Kampala, Uganda.
Caldwell B; Clinton Health Access Initiative, Kampala, Uganda.
Katureebe C; Ministry of Health, Kampala, Uganda.
Namuwenge N; Ministry of Health, Kampala, Uganda.
Atugonza R; Ministry of Health, Kampala, Uganda.
Musoke A; Clinton Health Access Initiative, Kampala, Uganda.
Musinguzi J; Ministry of Health, Kampala, Uganda.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 May 27; Vol. 15 (5), pp. e0232419. Date of Electronic Publication: 2020 May 27 (Print Publication: 2020).
Typ publikacji :
Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :
HIV Infections/*drug therapy
HIV Integrase Inhibitors/*therapeutic use
Heterocyclic Compounds, 3-Ring/*therapeutic use
Adult ; Antiretroviral Therapy, Highly Active/adverse effects ; Antiretroviral Therapy, Highly Active/methods ; Cohort Studies ; Female ; HIV Infections/virology ; HIV Integrase Inhibitors/adverse effects ; Heterocyclic Compounds, 3-Ring/adverse effects ; Humans ; Male ; Middle Aged ; Patient Acceptance of Health Care ; Pilot Projects ; Prospective Studies ; Uganda ; Viral Load/drug effects ; Young Adult
Czasopismo naukowe
Tytuł :
Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding.
Autorzy :
Chitongo R; South African Medical Research Council Bioinformatics Unit, South African National Bioinformatics Institute, University of the Western Cape, Cape Town, South Africa.
Obasa AE; Division of Medical Virology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa.
Mikasi SG; Division of Medical Virology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa.
Jacobs GB; Division of Medical Virology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa.
Cloete R; South African Medical Research Council Bioinformatics Unit, South African National Bioinformatics Institute, University of the Western Cape, Cape Town, South Africa.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 May 07; Vol. 15 (5), pp. e0223464. Date of Electronic Publication: 2020 May 07 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Mutation*
Drug Resistance, Viral/*genetics
HIV Infections/*metabolism
HIV Integrase/*genetics
HIV Integrase/*metabolism
HIV Integrase Inhibitors/*metabolism
HIV-1/*enzymology
Heterocyclic Compounds, 3-Ring/*metabolism
Amino Acid Sequence ; Catalytic Domain/genetics ; HIV Infections/drug therapy ; HIV Infections/virology ; HIV Integrase/chemistry ; HIV Integrase Inhibitors/therapeutic use ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Humans ; Molecular Dynamics Simulation ; Protein Binding/genetics ; Protein Stability ; Quinolones/metabolism ; Quinolones/therapeutic use ; Raltegravir Potassium/metabolism ; Raltegravir Potassium/therapeutic use ; South Africa ; Virus Replication/drug effects ; Virus Replication/genetics
Czasopismo naukowe
Tytuł :
β-catenin promotes NLRP3 inflammasome activation via increasing the association between NLRP3 and ASC.
Autorzy :
Huang L; Department of Hematology and Key Laboratory of Non-resolving Inflammation and Cancer of Hunan Province, the Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410000 PR China.
Luo R; Department of Hematology and Key Laboratory of Non-resolving Inflammation and Cancer of Hunan Province, the Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410000 PR China.
Li J; Department of Hematology and Key Laboratory of Non-resolving Inflammation and Cancer of Hunan Province, the Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410000 PR China.
Wang D; Department of Dermatology, the Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410000 PR China.
Zhang Y; Department of Hematology and Key Laboratory of Non-resolving Inflammation and Cancer of Hunan Province, the Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410000 PR China.
Liu L; Department of General Surgery, the Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410000 PR China.
Zhang N; Department of Blood Transfusion, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, 410000 PR China.
Xu X; Department of Hematology and Key Laboratory of Non-resolving Inflammation and Cancer of Hunan Province, the Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410000 PR China.
Lu B; Department of Hematology and Key Laboratory of Non-resolving Inflammation and Cancer of Hunan Province, the Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410000 PR China; Key Laboratory of Medical Genetics, School of Biological Science and Technology, Central South University, Changsha, Hunan Province, 410000 PR China; Key Laboratory of Sepsis and Translational Medicine, School of Basic Medical Science, Central South University, Changsha, Hunan Province, 410000 PR China; Department of Pathophysiology, School of Basic Medical Science, Jinan University, Guangzhou, Guangdong Province, 510632 PR China.
Zhao K; Department of Hematology and Key Laboratory of Non-resolving Inflammation and Cancer of Hunan Province, the Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410000 PR China. Electronic address: .
Pokaż więcej
Źródło :
Molecular immunology [Mol Immunol] 2020 May; Vol. 121, pp. 186-194. Date of Electronic Publication: 2020 Mar 31.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
CARD Signaling Adaptor Proteins/*metabolism
Heterocyclic Compounds, 3-Ring/*pharmacology
Inflammasomes/*immunology
Inflammation/*prevention & control
NLR Family, Pyrin Domain-Containing 3 Protein/*metabolism
beta Catenin/*metabolism
Animals ; CARD Signaling Adaptor Proteins/immunology ; Disease Models, Animal ; HEK293 Cells ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Humans ; Inflammasomes/drug effects ; Inflammation/immunology ; Injections, Intraperitoneal ; Lipopolysaccharides/immunology ; Macrophages/drug effects ; Macrophages/immunology ; Macrophages/metabolism ; Male ; Mice ; NLR Family, Pyrin Domain-Containing 3 Protein/immunology ; Primary Cell Culture ; RNA, Small Interfering/metabolism ; Recombinant Proteins/genetics ; Recombinant Proteins/metabolism ; Wnt Signaling Pathway/drug effects ; Wnt Signaling Pathway/immunology ; beta Catenin/antagonists & inhibitors ; beta Catenin/genetics
Czasopismo naukowe
Tytuł :
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
Autorzy :
Kintu K; Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Malaba TR; Division of Epidemiology and Biostatistics, University of Cape Town, Cape Town, South Africa.
Nakibuka J; Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Papamichael C; Tropical Clinical Trials Unit, Liverpool School of Tropical Medicine, Liverpool, UK.
Colbers A; Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, Netherlands.
Byrne K; Tropical Clinical Trials Unit, Liverpool School of Tropical Medicine, Liverpool, UK.
Seden K; Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
Hodel EM; Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
Chen T; Tropical Clinical Trials Unit, Liverpool School of Tropical Medicine, Liverpool, UK.
Twimukye A; Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Byamugisha J; Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda; Department of Gynaecology and Obstetrics School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
Reynolds H; Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.
Watson V; Tropical Clinical Trials Unit, Liverpool School of Tropical Medicine, Liverpool, UK.
Burger D; Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, Netherlands.
Wang D; Tropical Clinical Trials Unit, Liverpool School of Tropical Medicine, Liverpool, UK.
Waitt C; Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda; Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.
Taegtmeyer M; International Public Health, Liverpool School of Tropical Medicine, Liverpool, UK.
Orrell C; School of Public Health & Family Medicine, and Desmond Tutu HIV Centre, Department of Medicine, Institute of Infectious Diseases & Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Lamorde M; Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Myer L; Division of Epidemiology and Biostatistics, University of Cape Town, Cape Town, South Africa; Centre for Infectious Diseases Epidemiology and Research, University of Cape Town, Cape Town, South Africa.
Khoo S; Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK. Electronic address: .
Pokaż więcej
Corporate Authors :
DolPHIN-2 Study Group
Źródło :
The lancet. HIV [Lancet HIV] 2020 May; Vol. 7 (5), pp. e332-e339.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-HIV Agents/*therapeutic use
Benzoxazines/*therapeutic use
HIV Infections/*drug therapy
HIV Integrase Inhibitors/*therapeutic use
Heterocyclic Compounds, 3-Ring/*therapeutic use
Adult ; Anti-HIV Agents/adverse effects ; Benzoxazines/adverse effects ; Female ; HIV Infections/mortality ; HIV Integrase Inhibitors/adverse effects ; Heterocyclic Compounds, 3-Ring/adverse effects ; Humans ; Infant, Newborn ; Infectious Disease Transmission, Vertical/prevention & control ; Outcome Assessment, Health Care ; Pregnancy ; Pregnancy Outcome ; Pregnancy Trimester, Third ; Viral Load/drug effects
Czasopismo naukowe
Tytuł :
Arabidopsis FHY3 and FAR1 integrate light and strigolactone signaling to regulate branching.
Autorzy :
Xie Y; Biotechnology Research Institute, Chinese Academy of Agricultural Sciences, 100081, Beijing, China.
Liu Y; Biotechnology Research Institute, Chinese Academy of Agricultural Sciences, 100081, Beijing, China.
Ma M; Biotechnology Research Institute, Chinese Academy of Agricultural Sciences, 100081, Beijing, China.
Zhou Q; Graduate School of Chinese Academy of Agricultural Sciences, 100081, Beijing, China.
Zhao Y; Graduate School of Chinese Academy of Agricultural Sciences, 100081, Beijing, China.
Zhao B; Graduate School of Chinese Academy of Agricultural Sciences, 100081, Beijing, China.
Wang B; Biotechnology Research Institute, Chinese Academy of Agricultural Sciences, 100081, Beijing, China.
Wei H; State Key Laboratory for Conservation and Utilization of Subtropical Agro-Bioresources, South China Agricultural University, 510642, Guangzhou, China.
Wang H; State Key Laboratory for Conservation and Utilization of Subtropical Agro-Bioresources, South China Agricultural University, 510642, Guangzhou, China. .; Guangdong Laboratory for Lingnan Modern Agriculture, 510642, Guangzhou, China. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2020 Apr 23; Vol. 11 (1), pp. 1955. Date of Electronic Publication: 2020 Apr 23.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Signal Transduction*
Arabidopsis/*growth & development
Arabidopsis/*metabolism
Arabidopsis Proteins/*metabolism
Heterocyclic Compounds, 3-Ring/*metabolism
Lactones/*metabolism
Nuclear Proteins/*metabolism
Phytochrome/*metabolism
Arabidopsis/genetics ; Arabidopsis Proteins/genetics ; Gene Expression Regulation, Plant ; Heterocyclic Compounds, 3-Ring/antagonists & inhibitors ; Lactones/antagonists & inhibitors ; Light ; Light Signal Transduction ; Mutation ; Nuclear Proteins/genetics ; Phytochrome/genetics ; Plants, Genetically Modified ; Promoter Regions, Genetic ; Protein Binding ; Repressor Proteins/genetics ; Repressor Proteins/metabolism ; Trans-Activators/genetics ; Trans-Activators/metabolism ; Transcription Factors/genetics ; Transcription Factors/metabolism ; Transcriptional Activation
Czasopismo naukowe
Tytuł :
Dolutegravir and neural tube defects: a new insight.
Autorzy :
Chouchana L; Centre Regional de Pharmacovigilance, Assistance Publique-Hopitaux de Paris, Université de Paris, Hopital Cochin, Paris 75014, France. Electronic address: .
Pariente A; Université de Bordeaux, Inserm, Bordeaux Population Health Research Centre, Team Pharmacoepidemiology, UMR 1219, CHU de Bordeaux, Centre Regional de Pharmacovigilance de Bordeaux, Bordeaux, France.
Pannier E; Département d'obstétrique - Maternité Port-Royal, Assistance Publique-Hopitaux de Paris, Université de Paris, Hopital Cochin, Paris 75014, France.
Tsatsaris V; Département d'obstétrique - Maternité Port-Royal, Assistance Publique-Hopitaux de Paris, Université de Paris, Hopital Cochin, Paris 75014, France.
Treluyer JM; Centre Regional de Pharmacovigilance, Assistance Publique-Hopitaux de Paris, Université de Paris, Hopital Cochin, Paris 75014, France.
Pokaż więcej
Źródło :
The Lancet. Infectious diseases [Lancet Infect Dis] 2020 Apr; Vol. 20 (4), pp. 405-406.
Typ publikacji :
Letter
MeSH Terms :
Neural Tube Defects*/chemically induced
Neural Tube Defects*/epidemiology
Pharmacovigilance*
HIV Integrase Inhibitors/*adverse effects
Heterocyclic Compounds, 3-Ring/*adverse effects
Databases, Factual ; Developed Countries ; Developing Countries ; Female ; HIV Integrase Inhibitors/administration & dosage ; Heterocyclic Compounds, 3-Ring/administration & dosage ; Humans ; Viral Load
Opinia redakcyjna
Tytuł :
Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
Autorzy :
Phillips AN; Institute for Global Health, University College London, London, UK. Electronic address: .
Bansi-Matharu L; Institute for Global Health, University College London, London, UK.
Venter F; Ezintsha, Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa.
Havlir D; School of Medicine, University of California San Francisco, San Francisco, CA, USA.
Pozniak A; Chelsea and Westminster Hospital, London, UK; London School of Hygiene & Tropical Medicine, London, UK.
Kuritzkes DR; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Wensing A; Ezintsha, Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa; University Medical Center Utrecht, Utrecht, Netherlands.
Lundgren JD; Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Pillay D; Africa Health Research Institute, Mtubatuba, South Africa.
Mellors J; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PN, USA.
Cambiano V; Institute for Global Health, University College London, London, UK.
Jahn A; Ministry of Health, Lilongwe, Malawi.
Apollo T; Ministry of Health and Child Care, Harare, Zimbabwe.
Mugurungi O; Ministry of Health and Child Care, Harare, Zimbabwe.
Ripin D; Clinton Health Access Initiative, New York, NY, USA.
Da Silva J; Centers for Disease Control and Prevention, Atlanta, GA, USA.
Raizes E; Centers for Disease Control and Prevention, Atlanta, GA, USA.
Ford N; Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa; WHO, Geneva, Switzerland.
Siberry GK; Office of HIV/AIDS, Global Health Bureau, United States Agency for International Development, Arlington, VA, USA.
Gupta RK; Cambridge Institute of Immunology and Infectious Diseases, University of Cambridge, Cambridge, UK.
Barnabas R; Department of Global Health, University of Washington, Seattle, WA, USA.
Revill P; Centre for Health Economics, University of York, York, UK.
Cohn J; Elizabeth Glaser Paediatric Health Foundation, Washington, DC, USA.
Calmy A; HIV/AIDS Unit, Geneva University Hospital, University of Geneva, Geneva, Switzerland.
Bertagnolio S; WHO, Geneva, Switzerland.
Pokaż więcej
Źródło :
The lancet. HIV [Lancet HIV] 2020 Mar; Vol. 7 (3), pp. e193-e200. Date of Electronic Publication: 2020 Feb 05.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-HIV Agents/*administration & dosage
Benzoxazines/*administration & dosage
HIV Infections/*drug therapy
Heterocyclic Compounds, 3-Ring/*administration & dosage
Adolescent ; Adult ; Africa South of the Sahara ; Anti-HIV Agents/economics ; Benzoxazines/economics ; Cost-Benefit Analysis ; Female ; HIV Infections/economics ; HIV Infections/transmission ; Heterocyclic Compounds, 3-Ring/economics ; Humans ; Infectious Disease Transmission, Vertical/prevention & control ; Male ; Middle Aged ; Practice Guidelines as Topic ; Pregnancy ; Pregnancy Complications/drug therapy ; Pregnancy Complications/virology ; Randomized Controlled Trials as Topic ; Young Adult
Czasopismo naukowe
Tytuł :
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.
Autorzy :
Cahn P; Fundación Huesped, Buenos Aires, Argentina.
Madero JS; Departamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Arribas JR; Instituto de Investigación Hospital Universitario La Paz, Madrid, Spain.
Antinori A; Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani IRCCS, Rome, Italy.
Ortiz R; Bliss Healthcare Services, Orlando, FL.
Clarke AE; Royal Sussex County Hospital, Brighton, United Kingdom.; Brighton & Sussex Medical School, Brighton, United Kingdom.
Hung CC; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Rockstroh JK; Department of Medicine, Universitätsklinikum Bonn, Bonn, Germany.
Girard PM; Hôpital Saint Antoine, Paris, France.
Sievers J; Research & Development and Global Medical, ViiV Healthcare, Brentford, United Kingdom.
Man CY; Research & Development and Global Medical, ViiV Healthcare, Research Triangle Park, NC.
Urbaityte R; Pharma Research & Development, GlaxoSmithKline, Stockley Park, United Kingdom.
Brandon DJ; Pharma Research & Development, GlaxoSmithKline, Stockley Park, United Kingdom.
Underwood M; Research & Development and Global Medical, ViiV Healthcare, Research Triangle Park, NC.
Tenorio AR; Research & Development and Global Medical, ViiV Healthcare, Research Triangle Park, NC.
Pappa KA; Research & Development and Global Medical, ViiV Healthcare, Research Triangle Park, NC.
Wynne B; Research & Development and Global Medical, ViiV Healthcare, Research Triangle Park, NC.
Gartland M; Research & Development and Global Medical, ViiV Healthcare, Research Triangle Park, NC.
Aboud M; Research & Development and Global Medical, ViiV Healthcare, Brentford, United Kingdom.
van Wyk J; Research & Development and Global Medical, ViiV Healthcare, Brentford, United Kingdom.
Smith KY; Research & Development and Global Medical, ViiV Healthcare, Research Triangle Park, NC.
Pokaż więcej
Źródło :
Journal of acquired immune deficiency syndromes (1999) 2020 Mar 01; Vol. 83 (3), pp. 310-318.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
HIV-1*
HIV Infections/*drug therapy
Heterocyclic Compounds, 3-Ring/*therapeutic use
Lamivudine/*therapeutic use
Adolescent ; Adult ; Anti-HIV Agents/administration & dosage ; Anti-HIV Agents/therapeutic use ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Heterocyclic Compounds, 3-Ring/administration & dosage ; Humans ; Lamivudine/administration & dosage ; Male ; Middle Aged ; RNA, Viral/blood ; Young Adult
Czasopismo naukowe
Tytuł :
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.
Autorzy :
Galizzi N; Infectious Diseases, IRCCS San Raffaele Scientific Institute, Via Stamira d'Ancona 20, 20127 Milan, Italy.
Poli A; Infectious Diseases, IRCCS San Raffaele Scientific Institute, Via Stamira d'Ancona 20, 20127 Milan, Italy.
Galli L; Infectious Diseases, IRCCS San Raffaele Scientific Institute, Via Stamira d'Ancona 20, 20127 Milan, Italy.
Muccini C; Infectious Diseases, IRCCS San Raffaele Scientific Institute, Via Stamira d'Ancona 20, 20127 Milan, Italy; Vita-Salute San Raffaele University, Via Olgettina 58, 20132 Milan, Italy.
Mastrangelo A; Infectious Diseases, IRCCS San Raffaele Scientific Institute, Via Stamira d'Ancona 20, 20127 Milan, Italy; Vita-Salute San Raffaele University, Via Olgettina 58, 20132 Milan, Italy.
Dell'Acqua R; Infectious Diseases, IRCCS San Raffaele Scientific Institute, Via Stamira d'Ancona 20, 20127 Milan, Italy; University Hospital Policlinico, Piazza Giulio Cesare 11, 70124 Bari, Italy.
Maillard M; Infectious Diseases, IRCCS San Raffaele Scientific Institute, Via Stamira d'Ancona 20, 20127 Milan, Italy.
Bossolasco S; Infectious Diseases, IRCCS San Raffaele Scientific Institute, Via Stamira d'Ancona 20, 20127 Milan, Italy.
Cinque P; Infectious Diseases, IRCCS San Raffaele Scientific Institute, Via Stamira d'Ancona 20, 20127 Milan, Italy.
Lazzarin A; Infectious Diseases, IRCCS San Raffaele Scientific Institute, Via Stamira d'Ancona 20, 20127 Milan, Italy.
Castagna A; Infectious Diseases, IRCCS San Raffaele Scientific Institute, Via Stamira d'Ancona 20, 20127 Milan, Italy; Vita-Salute San Raffaele University, Via Olgettina 58, 20132 Milan, Italy.
Gianotti N; Infectious Diseases, IRCCS San Raffaele Scientific Institute, Via Stamira d'Ancona 20, 20127 Milan, Italy. Electronic address: .
Pokaż więcej
Źródło :
International journal of antimicrobial agents [Int J Antimicrob Agents] 2020 Mar; Vol. 55 (3), pp. 105893. Date of Electronic Publication: 2020 Jan 09.
Typ publikacji :
Journal Article
MeSH Terms :
Anti-HIV Agents/*therapeutic use
HIV Infections/*drug therapy
Heterocyclic Compounds, 3-Ring/*therapeutic use
Lamivudine/*therapeutic use
Reverse Transcriptase Inhibitors/*therapeutic use
Rilpivirine/*therapeutic use
Anti-HIV Agents/administration & dosage ; Drug Resistance, Viral ; Heterocyclic Compounds, 3-Ring/administration & dosage ; Humans ; Lamivudine/administration & dosage ; Retrospective Studies ; Rilpivirine/administration & dosage ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Insecticidal Endostemonines A-J Produced by Endophytic Streptomyces from Stemona sessilifolia .
Autorzy :
Zhao H; Jiangsu Key Laboratory for Functional Substances of Chinese Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization , Nanjing University of Chinese Medicine , Nanjing 210023 , People's Republic of China.
Yang A; Jiangsu Key Laboratory for Functional Substances of Chinese Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization , Nanjing University of Chinese Medicine , Nanjing 210023 , People's Republic of China.
Zhang N; Jiangsu Key Laboratory for Functional Substances of Chinese Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization , Nanjing University of Chinese Medicine , Nanjing 210023 , People's Republic of China.
Li S; Jiangsu Key Laboratory for Functional Substances of Chinese Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization , Nanjing University of Chinese Medicine , Nanjing 210023 , People's Republic of China.
Yuan T; Jiangsu Key Laboratory for Functional Substances of Chinese Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization , Nanjing University of Chinese Medicine , Nanjing 210023 , People's Republic of China.
Ding N; Jiangsu Key Laboratory for Functional Substances of Chinese Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization , Nanjing University of Chinese Medicine , Nanjing 210023 , People's Republic of China.
Zhang S; Jiangsu Key Laboratory for Functional Substances of Chinese Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization , Nanjing University of Chinese Medicine , Nanjing 210023 , People's Republic of China.
Bao S; Jiangsu Key Laboratory for Functional Substances of Chinese Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization , Nanjing University of Chinese Medicine , Nanjing 210023 , People's Republic of China.
Wang C; Jiangsu Key Laboratory for Functional Substances of Chinese Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization , Nanjing University of Chinese Medicine , Nanjing 210023 , People's Republic of China.
Zhang Y; Jiangsu Key Laboratory for Functional Substances of Chinese Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization , Nanjing University of Chinese Medicine , Nanjing 210023 , People's Republic of China.
Wang X; Jiangsu Key Laboratory for Functional Substances of Chinese Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization , Nanjing University of Chinese Medicine , Nanjing 210023 , People's Republic of China.
Hu L; Jiangsu Key Laboratory for Functional Substances of Chinese Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization , Nanjing University of Chinese Medicine , Nanjing 210023 , People's Republic of China.
Pokaż więcej
Źródło :
Journal of agricultural and food chemistry [J Agric Food Chem] 2020 Feb 12; Vol. 68 (6), pp. 1588-1595. Date of Electronic Publication: 2020 Jan 29.
Typ publikacji :
Journal Article
MeSH Terms :
Endophytes/*chemistry
Heterocyclic Compounds, 3-Ring/*metabolism
Insecticides/*metabolism
Stemonaceae/*microbiology
Streptomyces/*chemistry
Streptomyces/*metabolism
Animals ; Aphids/drug effects ; Endophytes/metabolism ; Heterocyclic Compounds, 3-Ring/chemistry ; Heterocyclic Compounds, 3-Ring/toxicity ; Insecticides/chemistry ; Insecticides/toxicity ; Secondary Metabolism
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies